Question for written answer E-003925/2021
to the Commission
Rule 138
Sergio Berlato (ECR)

Subject: 'Vaccine blackmail' meaningless when there are approved treatments capable of treating COVID-19

First of all, the conditional marketing authorisation for COVID-19 vaccines was granted, as provided for under the fast-track procedure, only on the basis of two requirements: high impact in terms of mortality and a total lack of available treatment.

As pointed out by the AIFA, monoclonal antibody treatments are capable of effectively combating COVID-19 and its variants and – as announced by the Commission itself – as many as three other new COVID-19 treatments could be authorised in October.

Can the Commission say:

1. why the EMA does not suspend the vaccines and order that their testing be resumed in the ordinary manner, given that one of the two essential 'fast-track' requirements, namely the total lack of available treatments, is no longer valid;

2. why it is not promoting the use of medicines to treat the coronavirus?